Search

Your search keyword '"Eric C. Kauffman"' showing total 67 results

Search Constraints

Start Over You searched for: Author "Eric C. Kauffman" Remove constraint Author: "Eric C. Kauffman"
67 results on '"Eric C. Kauffman"'

Search Results

1. Active Surveillance for Small Renal Masses

2. Iron accumulation typifies renal cell carcinoma tumorigenesis but abates with pathological progression, sarcomatoid dedifferentiation, and metastasis

3. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion

4. The Impact of Multiple Malignancies on Patients with Bladder Carcinoma: A Population-Based Study Using the SEER Database

5. Supplemental Figure 1 from Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma

6. Data from Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma

7. Supplemental Figure 2 from Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma

9. Supplemental Figure 3 from Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma

11. MP50-15 DEVELOPMENT AND VALIDATION OF AN OBJECTIVE SCORING TOOL FOR ROBOT ASSISTED PARTIAL NEPHRECTOMY: SCORING FOR PARTIAL NEPHRECTOMY (SPAN)

15. Postoperative Restrictive Opioid Protocols and Durable Changes in Opioid Prescribing and Chronic Opioid Use

16. Development and Validation of an Objective Scoring Tool for Robot-Assisted Partial Nephrectomy: Scoring for Partial Nephrectomy

17. Feasibility and continence outcomes of extended prostatic urethral preservation during robot-assisted radical prostatectomy

18. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma

19. Active surveillance for risk stratification of all small renal masses lacking predefined clinical criteria for intervention

20. Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma

21. Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients

22. Tobacco use and outcome in radical prostatectomy patients

23. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion

24. Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study

25. Less is more: Postoperative pain management using restrictive opioid protocols in all surgical services in a comprehensive cancer center

26. Outcomes of Scheduled vs For-Cause Biopsy Regimens for Prostate Cancer Active Surveillance

27. Outcomes of Minimal Invasive vs Open Radical Nephrectomy for the Treatment of Locally Advanced Renal-Cell Carcinoma

28. Implications of High Rates of Metastatic Prostate Cancer inBRCA2Mutation Carriers

29. Minimally invasive cytoreductive nephrectomy: a multi-institutional experience

30. Lack of Impact of Robotic Assisted Laparoscopic Radical Prostatectomy on Intraoperative Levels of Prostate Cancer Circulating Tumor Cells

31. Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer

32. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation

33. Development of a Patient-Based Model for Estimating Operative Times for Robot-Assisted Radical Prostatectomy

34. Incidence of Clear Cell Papillary Renal Cell Carcinoma in Low-Grade Renal Cell Carcinoma Cases

35. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers

36. Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC)

37. High-dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: A Contemporary Experience

38. External validation of preoperative and postoperative nomograms for prediction of cancer-specific survival, overall survival and recurrence after robot-assisted radical cystectomy for urothelial carcinoma of the bladder

39. Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential

40. A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results

41. Germline PTEN Mutation Cowden Syndrome: An Underappreciated Form of Hereditary Kidney Cancer

42. Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy

43. Mucinous Cystadenoma of the Urachus: A Case Report and Review of the Literature

44. Re: Clinical significance of prospectively assigned gleason tertiary pattern 4 in contemporary Gleason score 3 + 3 = 6 prostate cancer

45. Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers

46. Early oncological outcomes for bladder urothelial carcinoma patients treated with robotic-assisted radical cystectomy

47. Association of high CD8+ tumor infiltrating lymphocytes at prostatectomy with improved survival of prostate cancer patients

48. Gleason 6 Prostate Cancer: Translating Biology into Population Health

49. Early identification of asymptomatic brain metastases from renal cell carcinoma

50. Comparative Analysis of Smoking as a Risk Factor among Renal Cell Carcinoma Histological Subtypes

Catalog

Books, media, physical & digital resources